Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 8/20 | 1.00 |
| ▸ | SORT1 | Q99523 | 8/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13219146 | 0.90 | GRN (0.82) | GRNSORT1NPSR1GAAMAPT | |
| SCHEMBL893061 | 0.90 | GRN (0.82) | GRNSORT1NPSR1GAAMAPT | |
| 4-Chloroaniline SCHEMBL7744339 | 0.89 | GRN (0.79) | GRNSORT1NPSR1GAAMAPT | |
| SCHEMBL7739178 | 0.89 | GRN (0.79) | GRNSORT1NPSR1GAAMAPT | |
| SCHEMBL1897360 | 0.89 | GRN (0.80) | GRNSORT1NPSR1GAAMAPT | |
| SCHEMBL4490129 | 0.87 | GRN (0.78) | GRNSORT1NPSR1GAAMAPT | |
| SCHEMBL7744333 | 0.87 | GRN (0.76) | GRNSORT1NPSR1GAAMAPT | |
| SCHEMBL7739174 | 0.87 | GRN (0.76) | GRNSORT1NPSR1GAAMAPT | |
| SCHEMBL6925308 | 0.86 | GRN (0.76) | GRNSORT1NPSR1GAAMAPT | |
| SCHEMBL7746883 | 0.86 | NPSR1 (0.94) | GRNSORT1NPSR1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197700-A1 | Methods and Compositions for Treating Lysosomal Storage Disorders | HEALTH, SANFORD | 2024-06-20 | — | — | US | claimed |
| EP-4313016-A1 | METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISORDERS | Sanford Health (US) | 2024-02-07 | — | — | EP | claimed |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | VESPER BIO APS (DK) | 2023-11-23 | — | — | US | claimed |
| EP-4225280-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | Insusense ApS (DK) | 2023-08-16 | — | — | EP | claimed |
| CN-116194096-A | Sortilin antagonists for preventing and treating hearing impairment | 因苏森斯有限公司 | 2023-05-30 | — | — | CN | claimed |
| WO-2022212268-A1 | METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISORDERS | SANFORD HEALTH (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2022074119-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | INSUSENSE ApS (DK) | 2022-04-14 | — | — | WO | claimed |
| EP-3981394-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS. | Insusense ApS (DK) | 2022-04-13 | — | — | EP | claimed |
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | claimed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | claimed |
| US-20060223868-A1 | Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | claimed |
| EP-1622884-A1 | NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). | AstraZeneca AB (SE) | 2006-02-08 | — | — | EP | claimed |
| WO-2005123719-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-12-29 | — | — | WO | claimed |
| WO-2004096784-A1 | NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | claimed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | claimed |
| EP-1252156-A1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | University College London (GB) | 2002-10-30 | — | — | EP | claimed |
| WO-2001057024-A1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2001-08-09 | — | — | WO | claimed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | claimed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | claimed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | CACNA1F, SCNN1B, CACNA1B | GRN 2010/4885SORT1 2444/4885NPSR1 1816/4885 |
| US-20060223868-A1 | Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) | AVPR1A, AVPR2, TRPV1 | GRN 4173/4885SORT1 2850/4885NPSR1 27/4885 |
| US-20240197700-A1 | Methods and Compositions for Treating Lysosomal Storage Disorders | GAA, GBA1, MAN2B1 | GRN 208/4885SORT1 4/4885NPSR1 2111/4885 |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | SORT1, NTSR2, SLC17A5 | GRN 448/4885SORT1 1/4885NPSR1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.